{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"499"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"120"}]}],"title":"Participants experiencing at least one TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"22"}]}],"title":"Participants experiencing at least one serious TEAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"500"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"132"}],"units":"Participants"}],"description":"Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment.","groups":[{"description":"Induction Period (12 cycles): participants received lenalidomide 20 mg (10 mg if creatinine clearance ≥ 30 mL/min but \\< 60 mL/min) once daily on Days 1 to 21 of every 28-day Cycle for Cycles 1 to 12 AND rituximab 375 mg/m2 every week in Cycle 1 (Days 1, 8, 15, and 22) and Day 1 of every 28-day Cycle for Cycles 3, 5, 7, 9, and 11","id":"OG000","title":"Induction Period: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG001","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG002","title":"Arm B: Rituximab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)","title":"Participants Experiencing Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}